Core Viewpoint - BrightSpring Health Services, Inc. announced the pricing of a secondary offering of 14,000,000 shares at $21.75 per share, with proceeds going to the selling stockholders, including KKR affiliates and management members [1] Group 1: Offering Details - The offering is underwritten and will close on June 12, 2025, subject to customary closing conditions [1] - The KKR Selling Stockholder has granted underwriters a 30-day option to purchase an additional 2,100,000 shares [1] - No shares are being sold by BrightSpring itself in this offering [1] Group 2: Underwriters and Managers - Goldman Sachs & Co. LLC, BofA Securities, Jefferies, and Morgan Stanley & Co. LLC are the lead book-running managers for the offering [2] - KKR Capital Markets LLC is acting as the lead managing agent [2] - A number of other firms are participating as bookrunners and co-managers for the offering [2] Group 3: Registration and Compliance - A shelf registration statement was filed with the SEC on June 10, 2025, and became effective upon filing [3] - The offering will be made only by means of a prospectus supplement and accompanying prospectus [4]

LOUISVILLE, Ky., June 10, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services for complex populations, today announced that certain of its stockholders (the “Selling Stockholders”), including affiliates of Kohlberg Kravis Roberts & Co. L.P. (the “KKR Selling Stockholder”) and certain members of management, intend to offer for sale in an underwritten secondary offering an aggregate 14,000, ...

Core Viewpoint - BrightSpring Health Services, Inc. reported strong financial results for Q1 2025, with significant increases in revenue and adjusted EBITDA, and has raised its full-year guidance for revenue and adjusted EBITDA [1][6]. Financial Performance - Net Revenue for Q1 2025 reached $2,878 million, a 25.9% increase from $2,286 million in Q1 2024 [3][6]. - Gross Profit for the same period was $338 million, up 15.7% from $292 million in Q1 2024 [3][6]. - Net Income from Continuing Operations was $9.2 million, a turnaround from a Net Loss of $56.0 million in Q1 2024 [3][6]. - Adjusted EBITDA for Q1 2025 was $131 million, reflecting a 28.2% increase compared to $102 million in Q1 2024 [4][6]. Segment Performance - Pharmacy Solutions Revenue was $2,532 million, up 28% from $1,977 million in Q1 2024 [5]. - Provider Services Revenue increased by 12% to $346 million from $309 million in Q1 2024 [5]. Guidance and Future Outlook - The company has increased its 2025 Revenue guidance to a range of $12,000 million to $12,500 million, representing a growth of 19.1% to 24.1% [6][14]. - Adjusted EBITDA guidance for 2025 is now set at $570 million to $585 million, indicating a growth of 23.9% to 27.2% [6][14]. Strategic Initiatives - The planned divestiture of the Community Living business to Sevita is on track to be completed within the year [6].